News
FDA approves Odactra to treat house dust mite (HDM)-induced allergic rhinitis
ODACTRA is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites or by positive skin testing to licensed house dust mite allergen extracts
ODACTRA is approved for use in persons 12 through 65 years of age.
Condition: Allergic Rhinitis/Dust Mite
Type: drug